Loading...
Please wait, while we are loading the content...
Similar Documents
The association of glucagon with disease severity and progression in patients with autosomal dominant polycystic kidney disease: an observational cohort study
| Content Provider | Oxford Academic |
|---|---|
| Author | Knol, Martine G E Kramers, Bart J Gansevoort, Ron T van Gastel, Maatje D A |
| Copyright Year | 2021 |
| Abstract | Background: Mammalian target of rapamycin (mTOR) inhibitors and ketogenesis have been shown to ameliorate disease progression in experimental autosomal dominant polycystic kidney disease (ADPKD). Glucagon is known to lower mTOR activity and stimulate ketogenesis. We hypothesized that in ADPKD patients, higher endogenous glucagon is associated with less disease severity and progression.MethodsData were analysed from 664 Dutch ADPKD patients participating in the Developing Intervention Strategies to Halt Progression of ADPKD observational cohort, including patients >18 years of age with an estimated glomerular filtration rate (eGFR) ≥15 mL/min/1.73 m2 and excluding patients with concomitant diseases or medication use that may impact the natural course of ADPKD. The association between glucagon and disease severity and progression was tested using multivariate linear regression and mixed modelling, respectively.ResultsThe median glucagon concentration was 5.0 pmol/L [interquartile range (IQR) 3.4–7.2) and differed significantly between females and males [4.3 pmol/L (IQR 2.9–6.0) and 6.6 (4.5–9.5), P < 0.001, respectively]. Intrasubject stability of glucagon in 30 patients showed a strong correlation (Pearson's correlation coefficient 0.893; P < 0.001). Moreover, glucagon showed significant associations with known determinants (sex, body mass index and copeptin; all P < 0.01) and known downstream effects (glucose, haemoglobin A1c and cholesterol; all P < 0.05), suggesting that glucagon was measured reliably. Cross-sectionally, glucagon was associated with eGFR and height-adjusted total kidney volume, but in the opposite direction of our hypothesis, and these lost significance after adjustment for confounders. Glucagon was not associated with an annual decline in kidney function or growth in kidney volume.ConclusionsThese data do not provide evidence for a role of endogenous glucagon as a protective hormone in ADPKD. Intervention studies are needed to determine the relation between glucagon and ADPKD. |
| Related Links | https://academic.oup.com/ckj/article-pdf/14/12/2582/41838014/sfab112.pdf |
| Ending Page | 2590 |
| Starting Page | 2582 |
| File Format | |
| ISSN | 20488505 |
| e-ISSN | 20488513 |
| DOI | 10.1093/ckj/sfab112 |
| Journal | Clinical Kidney Journal |
| Issue Number | 12 |
| Volume Number | 14 |
| Language | English |
| Publisher | Oxford Academic |
| Publisher Date | 2021-12-21 |
| Access Restriction | Open |
| Subject Keyword | Clinical Medicine Medicine and Health Nephrology Glucagon Polycystic Kidney, Autosomal Dominant Severity of Illness Kidney Adpkd Egfr Estimated Glomerular Filtration Rate Pkd Polycystic Kidney Disease Tkv Total Kidney Volume |
| Content Type | Text |
| Resource Type | Article |
| Subject | Transplantation Nephrology |
